Trials / Completed
CompletedNCT00384592
PPI Sequencing Study
A Study to Assess the Effectiveness of Esomeprazole 40 mg Once Daily in Subjects With Continuing Gastroesophageal Reflux Disease (GORD) Symptoms Following Treatment Wit a Previous Full Dose Proton Pump Inhibitor (PPI)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole | |
| PROCEDURE | Physical exam | |
| PROCEDURE | Pregnancy test if applicable |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2006-10-06
- Last updated
- 2009-03-11
Locations
14 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00384592. Inclusion in this directory is not an endorsement.